Abbreviations: AUC, area under the curve; CV, coefficient of variation; GIR, glucose infusion rate; GIR max , maximal GIR; GIR t max , time to maximal GIR.
I
nsulin molecules can be absorbed into the blood stream after inhalation from the alveoli (1) . In a previous study, we showed that inhalation of an insulin powder aerosol containing solid insulin particles (99 U) led to a relative bioavailability of 7.8 ± 3.5% and a relative bioefficacy of 7.6 ± 2.9% (2) . This bioefficacy was comparable with that achieved with nasal insulin administration using absorption enhancers but implies that a large amount of insulin has to be used with either administration form to achieve a sufficient metabolic effect (3) (4) (5) (6) (7) . Nevertheless, the time-action profile seen with inhalation of insulin showed promising properties (i.e., a rapid onset of action and a relatively long duration of action).
Coadministration of nonionic surfactants increased insulin absorption after inhalation 3-to 4-fold in animal experiments (8) . Thus, the use of an absorption enhancer may increase bioavailability and bioefficacy considerably and would probably also improve the time-action profile of inhaled insulin. This study in healthy subjects investigated the bioavailability, bioefficacy, and within-subject variability of response to inhaled biosynthetic insulin with an absorption enhancer (bile salt, an endogenous substance) in comparison with intravenous and subcutaneous administration of insulin.
RESEARCH DESIGN AND METHODS

Subjects
This single-center study was open and randomized and had a 5-period crossover design. A total of 13 healthy subjects (age 27 ± 3 years [range 23-34], BMI 22.7 ± 2.0 kg/m 2 [19.4-26.2] , weight 73 ± 9 kg [55-85], normal lung function [forced expiratory volume (FEV 1 ) 4.6 ± 0.5 liters (3.8-5.3)], 104 ± 10% of the predicted value, all insulin IgG antibody negative, all nonsmokers [urine cotinine negative]) were randomized. Written informed consent was given by the volunteers after a detailed explanation of the study procedures. The study was approved by the local ethics committee and was carried out according to the principles of the Declaration of Helsinki and of good clinical practice.
Study protocol
After an overnight fast, the subjects came to the clinic and were connected to a Biostator (Life Science Instruments, Elkhardt, IN) (target blood glucose 5.0 mmol/l, continuous
Intra-individual Variability of the Metabolic Effect of Inhaled Insulin Together With an Absorption Enhancer O R I G I N A L A R T I C L E
OBJECTIVE -To study the metabolic effect and the variability of the effect elicited by inhalation of 87.2 U insulin powder combined with an absorption enhancer. The metabolic effect was compared with that of 10.2 U regular insulin injected subcutaneously and of 5.5 U regular insulin given intravenously.
RESEARCH DESIGN AND METHODS -In this single
-center open euglycemic glucose clamp study, 13 healthy male volunteers received 5 insulin administrations on separate study days: once as an intravenous dose, once as a subcutaneous injection, and 3 times by inhalation, in randomized order. Glucose infusion rates (GIRs) necessary to keep blood glucose concentrations constant at 5.0 mmol/l were determined over an 8-h period after administration.
RESULTS -After inhalation of the insulin powder aerosol, the onset of action was substantially more rapid than after subcutaneous insulin injection, and maximal action was reached earlier (86 ± 47 vs. 182 ± 53 min, P Ͻ 0.0001). The maximal glucose infusion rate after inhalation of insulin was comparable to that after subcutaneous insulin injection (9.2 ± 2.6 vs. 8.8 ± 2.8 mg и kg Ϫ1 и min Ϫ1 , NS). The metabolic effect in the first 2 h after inhalation was significantly greater than that after subcutaneous insulin injection (amount of glucose infused: 0.88 ± 0.25 vs. 0.59 ± 0.20 g и kg Ϫ1 и 120 min Ϫ1 , P Ͻ 0.0001). However, the total metabolic effect after inhalation and subcutaneous injection was comparable (2.50 ± 0.76 vs. 2.56 ± 0.69 g и kg Ϫ1 и 480 min Ϫ1 , NS). The relative bioefficacy of inhaled insulin calculated in relation to the data from the subcutaneous insulin application was 12.0 ± 3.5% (absolute bioefficacy 10.1 ± 3.1%) but was highest in the first 2 h after application (18.5 ± 3.7%; absolute bioefficacy 8.2 ± 4.1%). The intraindividual variability of the metabolic response induced by insulin inhalation was 14 ± 9% for the maximal glucose infusion rate, 15 ± 10% for the time-to-maximal effect, and 16 ± 12% for the total amount of glucose infused.
CONCLUSIONS -This feasibility study shows that inhaled insulin with an absorption enhancer has a pronounced metabolic effect compared with the results of a previous study of inhaled insulin without an enhancer. The intraindividual variability of the metabolic effect was comparable with that of inhaled and subcutaneously injected insulin. . On these study days, the volunteers inhaled 4 puffs of insulin powder (21.8 U insulin per inhalation) by means of an inspiratory flow-driven multi-dose dry powder inhaler. The variation in the delivered dose in vitro for the specific batch was 11%. The volunteers were instructed to inhale deeply and forcefully after a deep expiration and to hold their breath for 5-10 s. The metabolic effect of the applied insulin was assessed with the glucose infusion rates (GIRs) registered during the subsequent 480 min. Blood glucose concentrations were estimated continuously by the Biostator, and these measurements were checked using a laboratory system (APEC Glucose Analyser; Ruhrtal Labor Technik, Dreihausen, Germany). Serum insulin and serum C-peptide concentrations were measured by standard radioimmunoassays. The study protocol used in this study was comparable to that which we used in a previous study (2) .
Statistical methods
After correction for baseline GIR, a polynomial function (sixth order) was fitted to each individual GIR profile obtained. Fitting of this function allowed the estimation of pharmacodynamic summary measures: maximal GIR (GIR max ), time-to-GIR max (GIR t max ), and time-to-half-maximal values before and after GIR max was reached (early and late t 50% ). The area under the curve (AUC) GIR time profiles were calculated using the trapezoidal rule. An analysis of variance model with subject, period, and treatment as fixed factors was used for statistical analysis. Statistical significance was assumed at P Ͻ 0.05. The work by Heinemann et al. (2) provides details for the calculation of bioefficacy. The analysis of pharmacokinetic data was performed accordingly. The withinsubject coefficients of variation (CVs) for the parameters estimated were calculated from the data obtained on the 3 study days with inhalations.
RESULTS
Pharmacodynamic results
Baseline glucose requirements were comparable for all 3 methods of insulin administration (Table 1) . Inhaled insulin gave a rapid increase in glucose consumption, similar to that seen with intravenous insulin (Fig. 1A) . Time to maximal glucose consumption (GIR t max ) was shorter after insulin inhalation than after subcutaneous administration. Early t 50% and late t 50% also occurred earlier with inhalation, whereas the GIR max and the total amount of glucose infused were comparable. The decline in glucose consumption after insulin inhalation was slower than that with intravenous insulin and only moderately faster than that with subcutaneous insulin. After 8 h, glucose infusion rates were similar with all 3 administration methods but had not returned to baseline values. Glucose consumption in the first 120 min after insulin inhalation was greater than that after subcutaneous injection, but the total amount of glucose infused over the 8 h after insulin inhalation was comparable to that after subcutaneous insulin injection.
Absolute bioefficacy after insulin inhalation was 10.1 ± 3.1% and relative bioefficacy was 12.0 ± 3.5%. Within the first 2 h after administration, absolute bioefficacy was 8.2 ± 4.1%, and relative bioefficacy was 18.5 ± 3.7%. The intraindividual CV of absolute and relative bioefficacy was 16 ± 12% for the entire study duration and 13 ± 8% for the first 2 h after administration. The intraindividual variability of the metabolic response induced by insulin inhalation was 14 ± 9% for the maximal glucose infusion rate, 15 ± 10% for the time to maximal effect, and 16 ± 12% for the total amount of glucose infused.
Pharmacokinetic results
Starting from comparable baseline serum insulin concentrations, inhalation of insulin resulted in a more rapid increase to higher maximal values than subcutaneous insulin administration (Fig. 1B , Table 1 ). The serum insulin profiles for the 2 modes of administration were comparable after 90 min, with a slow decline thereafter. After 8 h, serum insulin levels were still a little higher than baseline levels. The AUC of the serum insulin profiles for the first 120 min after administration and also the total AUC was greater with inhaled insulin than with subcutaneous insulin injection. Absolute bioavailability of insulin after inhalation was estimated to be 10.2 ± 5.0% and relative bioavailability 14.5 ± 4.4% (intraindividual CV 19 ± 6%). During the first 2 h after inhalation, absolute bioavailability was estimated to be 6.4 ± 2.3% and relative bioavailability to be 25.1 ± 10.7%, reflecting the different time-action profiles obtained with the 2 methods of administration (intraindividual CV 17 ± 6%). After insulin inhalation, the intraindividual variability was 19 ± 7% for the maximal serum insulin concentrations, 25 ± 12% for the time to maximal levels, and 19 ± 6% for the total area under the serum insulin levels.
The continuous baseline intravenous insulin infusion and the administered insulin resulted in mean serum C-peptide levels of Ͻ0.6 nmol/l throughout the experiments with all forms of administration.
Tolerability of insulin inhalation
The insulin inhalation was generally well tolerated by the volunteers (i.e., no adverse event pattern that could be related to this form of administration was observed).
CONCLUSIONS -Inhalation is a novel administration form for insulin that is under clinical development. Important questions with this kind of administration are as follows: 1) Does it induce a sufficient metabolic effect relatively rapidly after administration, allowing sufficient prandial insulin substitution? 2) Is the variability of the induced metabolic effect comparable to that after subcutaneous insulin injection?
Our feasibility study demonstrated for the first time in humans that the addition of an absorption enhancer leads to a considerably greater metabolic effect than that seen with inhalation of pure insulin, which was previously studied (2) . The observed relative bioefficacy was 7.6% for the 360-min duration of the study with inhalation of pure insulin, compared with 12.0% in this study (duration 480 min). To show the differences in glucose consumption in the 2 studies, mean GIRs and serum insulin concentrations registered with inhalation of pure insulin and insulin with an absorption enhancer are given in Fig. 2A and B. The difference in metabolic action is especially pronounced in the first 2 h after inhalation, which is the critical time period in which to limit postprandial glycemic excursions. In other words, the total metabolic activity induced might be comparable with different insulin administration forms, but the time when this activity occurs is important.
Appropriately designed meal-related studies with diabetic patients are necessary to examine whether the greater metabolic effect soon after administration gives a better postprandial metabolic control than subcutaneous injection of regular insulin (or rapid-acting insulin analogs) (9) (10) (11) .
The onset of action seen with insulin plus the absorption enhancer after inhalation of the insulin powder aerosol was similar to or even more rapid than that seen with rapid-acting insulin analogs given by subcutaneous injection, but the 
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decline in metabolic activity seems to be slower (12) (13) (14) .
In other studies with inhaled insulin, without an absorption enhancer, a relative bioavailability of ϳ10% was reported (15) (16) (17) . In these studies, bioefficacy was estimated as a decline in blood glucose (i.e., stimulation of counterregulatory hormones might have occurred, allowing no precise description of the pharmacodynamic properties of the insulin preparations used) (18) . Thus, the results of such studies are difficult to compare with our data.
Inhalation of insulin was well tolerated in our study. The enhancer used is an endogenous substance (bile salt). However, use of an absorption enhancer gives rise to safety concerns. There are no data on the long-term effects of inhaling considerable amounts of bile salt (and insulin) over extended periods of time. If this substance has any negative effects, they are currently unknown and it remains to be clarified whether the benefits outweigh the risks of using an additional substance.
Insulin inhalation led to a good reproducibility of the metabolic effect induced, at least under our controlled experimental conditions. The within-subject variability after inhalation was about the same for the total amount of glucose infused (CV 16%) as for the total AUC under the serum insulin profile (19%). Quantitative information about the intraindividual variability of the metabolic effects induced by subcutaneous injection of regular insulin is limited (19, 20) . In a study that we performed under similar conditions in healthy subjects, the within-subject variability was evaluated after subcutaneous administration of regular insulin or of the rapid-acting insulin analog insulin aspart in identical doses on 4 study days (21) . The intraindividual CVs obtained in that study were comparable to those seen with inhaled insulin.
In summary, inhalation of an insulin powder aerosol with an absorption enhancer led to a pronounced metabolic effect soon after administration. The variability in the induced metabolic effect was comparable to that of regular insulin after subcutaneous administration. This feasibility study indicates that the powder aerosol used might be beneficial for prandial insulin substitution in patients with type 2 diabetes who are reluctant to take injections and, therefore, use oral drugs even if insulin therapy is indicated. DIABETES CARE, VOLUME 23, NUMBER 9, SEPTEMBER 2000 
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